Neurogene Inc. Net Income Loss

• Neurogene Inc. showed a decrease of -20.2% in Net Income Loss from 2024 to 2025.
• This data is from Neurogene Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2026.
• XBRL data for this metric is available from 2012 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2016: -$6.71 million | Q2 2016: -$10.90 million | Q3 2016: -$8.15 million | Q1 2017: -$8.32 million | Q2 2017: -$13.77 million | Q3 2017: -$11.83 million | Q1 2018: -$14.62 million | Q2 2018: $2.92 million | Q3 2018: -$14.99 million | Q1 2019: -$2.21 million | Q2 2019: -$1.0 thousand | Q3 2019: -$59.13 million | Q1 2020: -$8.64 million | Q2 2020: -$9.75 million | Q3 2020: -$2.25 million | Q1 2021: -$14.95 million | Q2 2021: -$15.13 million | Q3 2021: -$15.45 million | Q1 2022: -$15.35 million | Q2 2022: -$15.69 million | Q3 2022: -$13.07 million | Q1 2023: -$12.26 million | Q2 2023: -$11.86 million | Q3 2023: -$14.58 million | Q1 2024: -$16.92 million | Q2 2024: -$18.49 million | Q3 2024: -$20.22 million | Q1 2025: -$22.65 million | Q2 2025: -$22.02 million | Q3 2025: -$20.95 million.
• Over the full 15 years of available data (2012 to 2025), Neurogene Inc.'s Net Income Loss has declined by 1,071.2%.
• Historical annual values: Fiscal year 2025: -$90.35 million | Fiscal year 2024: -$75.14 million | Fiscal year 2023: $13.65 million | Fiscal year 2023: -$36.32 million | Fiscal year 2022: -$55.19 million | Fiscal year 2021: -$60.69 million | Fiscal year 2020: -$33.28 million | Fiscal year 2019: -$69.44 million | Fiscal year 2018: -$31.59 million | Fiscal year 2017: -$50.18 million | Fiscal year 2016: -$37.00 million | Fiscal year 2015: -$21.86 million | Fiscal year 2014: -$24.03 million | Fiscal year 2013: -$8.73 million | Fiscal year 2012: -$7.71 million.
• Data sourced from SEC EDGAR public filings as of August 8, 2026.

Last verified: August 8, 2026